ESR1 and breast carcinoma: In contrast to earlier studies concentrating solely on either inhibitory or promotional growth impacts of FGF ligands and their mechanisms on specific cell lines [18, 20–22], our research took a different approach aiming to unravel the reasons behind the dual promotional and inhibitory effects of FGF ligands in ER + breast cancer.